Hybrids of 3α-methoxyserrat-14-en-21β-ol (PJ-1) and 3β-methoxyserrat-14-en-21β-ol (PJ-2) and various anti-oxidants as cancer chemopreventive agents

Tsujii, Hiroko; Yamada, Takeshi; Kajimoto, Tetsuya; Tanaka, Reiko; Tokuda, Harukuni; Hasegawa, Junya; Hamashima, Yoshio; Node, Manabu

doi:10.1016/j.ejmech.2010.01.057

Cited by 6 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that baicalein inhibited mouse skin tumors in an in vivo two-stage carcinogenesis model [27]. Pretreatment of mouse skin with various amounts of baicalein caused inhibition of H 2 O 2 and myeloperoxidase formation by 12-O-tetradecanoylphorbol-13-acetate.…”

Section: Discussionmentioning

confidence: 99%

“…Bacailein has an inhibitory effect on lung cancer [20], colorectal cancer [21], gastric cancer [22], ovarian cancer [23], breast cancer [24], prostate cancer, and skin cancer [25,26]. Baicalein was also shown to inhibit the Epstein-Barr virus (EBV) early antigen activation induced by 12-O-tetradecanoylphorbol-13-acetate, and inhibit mouse skin tumors in an in vivo two-stage carcinogenesis model [27]. In particular, it was found that its anti-tumor effects in skin cancer were associated with inhibition of the p12-LOX pathway [28].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

RETRACTED ARTICLE: Baicalein mediates inhibition of migration and invasiveness of skin carcinoma through Ezrin in A431 cells

Huang

et al. 2011

BMC Cancer

View full text Add to dashboard Cite

BackgroundEzrin is highly expressed in skin cancer and promotes tumor metastasis. Ezrin serves as a promising target for anti-metastasis therapy. The aim of this study is to determine if the flavonoid bacailein inhibits the metastasis of skin cancer cells through Ezrin.MethodsCells from a cutaneous squamous carcinoma cell line, A431, were treated with baicalein at 0-60 μM to establish the non-cytotoxic concentration (NCC) range for baicalein. Following treatment with baicalein within this range, total Ezrin protein (both phosphorylated and unphosphorylated forms) and phosphorylated-Ezrin (phos-Ezrin) were detected by western blotting, and Ezrin RNA was detected in A431 cells using reverse transcription-polymerase chain reaction (RT-PCR). Thereafter, the motility and invasiveness of A431 cells following baicalein treatment were determined using wound-healing and Boyden chamber invasion assays. Short-interfering RNA (si-RNA) specifically targeting Ezrin was transfected into A431 cells, and a si-RNA Ezrin-A431 cell line was established by G418 selection. This stable cell line was transiently transfected with Ezrin and mutant Ezrin plasmids, and its motilityand invasiveness was subsequently determined to clarify whether bacailein inhibits these processes through Ezrin.ResultsWe determined the range of NCCs for baicalein to be 2.5-40 μM in A431 cells. Baicalein displayed a dose- and time-dependent inhibition of expressions of total Ezrin and phos-Ezrin within this range NCCs. In addition, it exerted this inhibitory effect through the reduction of Ezrin RNA transcript. Baicalein also inhibited the motility and invasiveness of A431 skin carcinoma cells within the range of NCCs, in a dose- and time-dependent manner. A431 cell motility and invasiveness were inhibited by 73% and 80% respectively when cells were treated with 20 μM baicalein. However, the motility and invasiveness of A431 cells containing the Ezrin mutant were not effectively inhibited by baicalein.ConclusionsBaicalein reduces the migration and invasiveness of A431 cells through the inhibition of Ezrin expression, which leads to the suppression of tumor metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Baicalein mediates inhibition of migration and invasiveness of skin carcinoma through Ezrin in A431 cells

Huang

et al. 2011

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…The evaluation of the effect of 3α- and 3β-methoxyserrat-14-en-21β-ol-curcumin conjugates on Epstein-Barr virus early antigen activation (EBV-EA) induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) revealed that such curcumin conjugates exhibited dose-dependent inhibitory activities; however, their cytotoxic potential against Raji cells appeared moderate in vitro by comparison with the results obtained for quercetin conjugates designed with the same triterpenoids [137]. Similarly, the conjugation, through an ester linkage, of curcumin to paclitaxel, a natural chemotherapeutic drug already used in the clinic, did not improve either the antioxidant or the cytotoxic properties of paclitaxel [138], whereas its conjugation with camptothecin resulted in a five-fold increase of cytotoxicity against human prostate carcinoma PC-3 cells and in decreased side effects on normal cells compared to the original paclitaxel molecule [139].…”

Section: Multifunctional Curcumin Molecules In the War Against Cancermentioning

confidence: 99%

Hybrid Curcumin Compounds: A New Strategy for Cancer Treatment

2014

View full text Add to dashboard Cite

Abstract:Cancer is a multifactorial disease that requires treatments able to target multiple intracellular components and signaling pathways. The natural compound, curcumin, was already described as a promising anticancer agent due to its multipotent properties and huge amount of molecular targets in vitro. Its translation to the clinic is, however, limited by its reduced solubility and bioavailability in patients. In order to overcome these pharmacokinetic deficits of curcumin, several strategies, such as the design of synthetic analogs, the combination with specific adjuvants or nano-formulations, have been developed. By taking into account the risk-benefit profile of drug combinations, as well as the knowledge about curcumin's structure-activity relationship, a new concept for the combination of curcumin with scaffolds from different natural products or components has emerged. The concept of a hybrid curcumin molecule is based on the incorporation or combination of curcumin with specific antibodies, adjuvants or other natural products already used or not in conventional chemotherapy, in one single molecule. The high diversity of such conjugations enhances the selectivity and inherent biological activities and properties, as well as the efficacy of the parental compound, with particular emphasis on improving the efficacy of curcumin for future clinical treatments.

show abstract

Natural Products Molten Together: Toward Multifunctional Hybrid Molecules with Specific Activities and Applications

Kirsch

2014

Recent Advances in Redox Active Plant and Microbial Products

View full text Add to dashboard Cite

Hybrids of 3α-methoxyserrat-14-en-21β-ol (PJ-1) and 3β-methoxyserrat-14-en-21β-ol (PJ-2) and various anti-oxidants as cancer chemopreventive agents

Cited by 6 publications

References 28 publications

RETRACTED ARTICLE: Baicalein mediates inhibition of migration and invasiveness of skin carcinoma through Ezrin in A431 cells

RETRACTED ARTICLE: Baicalein mediates inhibition of migration and invasiveness of skin carcinoma through Ezrin in A431 cells

Hybrid Curcumin Compounds: A New Strategy for Cancer Treatment

Natural Products Molten Together: Toward Multifunctional Hybrid Molecules with Specific Activities and Applications

Contact Info

Product

Resources

About